Clinical Trials Logo

Hand, Foot and Mouth Disease clinical trials

View clinical trials related to Hand, Foot and Mouth Disease.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT06209398 Active, not recruiting - Clinical trials for Hand, Foot and Mouth Disease

Immunogenicity of the Inactivated EV71 Vaccine Combined With Hepatitis B and Group A Meningococcal Vaccine

Start date: May 24, 2018
Phase: Phase 4
Study type: Interventional

The main purpose of this study is to evaluate the immunogenicity and safety of inactivated enterovirus type 71 vaccine combined with recombinant hepatitis B vaccine or Group a meningococcal polysaccharide vaccine.

NCT ID: NCT03240744 Active, not recruiting - Clinical trials for Hand, Foot and Mouth Disease (HFMD)

The Phase IVc of Inactivated Enterovirus 71 Vaccine (Human Diploid Cell)

Start date: June 22, 2017
Phase: Phase 4
Study type: Interventional

Enterovirus 71 (EV71), a major pathogen causing hand-foot-and-mouth disease (HFMD) worldwide, is a member of the Human Enterovirus species A, family Picornaviridae. Its infection occasionally leads to severe diseases and death, with central nervous system (CNS) damage. Recently, except of inactivated vaccine, several EV71 vaccine candidates have been evaluated in animals but no final results of clinical trials, such as attenuated vaccine, subunit vaccine. A formalin-inactivated EV71 vaccine (Human Diploid cell, KMB-17 Cell) has been finished phase I, II and III clinical trials and licensed by SFDA in China at Dec. 3, 2015. Based on the results of clinical trials, the protective efficacy of inactivated EV71 vaccine is 97% against HFMD caused by EV71. The phase IV clinical trial has been carried out from July 2016. The purpose of phase IVc is to evaluated the immunogenicity of the inactive EV71 vaccine in large scale population of Chinese children (from 6 to 71 months old) in Hubei Province, China.